Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System.

Akash KatarukaDhruv MahttaJulia M AkeroydRavi S HiraDhruv S KaziJohn A SpertusDeepak L BhattLaura A PetersenChristie M BallantyneSalim S Virani

Published in: Cardiovascular drugs and therapy (2020)

Over one third of patients with stable ASCVD may qualify for low-dose rivaroxaban within the VA. Additional studies are needed to understand eligibility in other populations and a formal cost-effectiveness analysis is warranted.

Keyphrases

low dose
venous thromboembolism
atrial fibrillation
high dose
pulmonary embolism
study protocol
phase iii
randomized controlled trial
phase ii
data analysis